{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:48:49Z","timestamp":1762505329077},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3081,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1038\/mt.2008.32","type":"journal-article","created":{"date-parts":[[2008,4,3]],"date-time":"2008-04-03T18:27:54Z","timestamp":1207247274000},"page":"985-994","source":"Crossref","is-referenced-by-count":39,"title":["Intralesional Adenovirus-mediated Interleukin-2 Gene Transfer for Advanced Solid Cancers and Melanoma"],"prefix":"10.1016","volume":"16","author":[{"given":"Reinhard","family":"Dummer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Rochlitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Velu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Acres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Limacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Bleuzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gis\u00e8le","family":"Lacoste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Slos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana","family":"Urosevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2008.32_bib1","first-page":"67","article-title":"Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors","volume":"75","author":"Rayner","year":"1985","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mt.2008.32_bib2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.161.5.1169","article-title":"Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2","volume":"161","author":"Rosenberg","year":"1985","journal-title":"J Exp Med"},{"key":"10.1038\/mt.2008.32_bib3","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2008.32_bib4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2008.32_bib5","doi-asserted-by":"crossref","first-page":"8522","DOI":"10.1073\/pnas.92.18.8522","article-title":"Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model","volume":"92","author":"Addison","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2008.32_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1089\/hum.1993.4.6-703","article-title":"Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice","volume":"4","author":"Haddada","year":"1993","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2008.32_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.gt.3300833","article-title":"Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial","volume":"6","author":"Stewart","year":"1999","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2008.32_bib8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.cgt.7700626","article-title":"A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer","volume":"10","author":"Trudel","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2008.32_bib9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-\u03b3 gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"key":"10.1038\/mt.2008.32_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/10430340152712719","article-title":"A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency","volume":"13","author":"Raper","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2008.32_bib11","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","article-title":"Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance","volume":"109","author":"Othman","year":"2007","journal-title":"Blood"},{"key":"10.1038\/mt.2008.32_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI32077","article-title":"Type I interferon innate response to adenoviral vector contributes to the regression of cutaneous lymphomas following adenovirus-mediated interferon-\u03b3 gene transfer","author":"Urosevic","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2008.32_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cncr.10178","article-title":"Immunotherapy for nonmelanoma skin cancer: does it have a future?","volume":"94","author":"Urosevic","year":"2002","journal-title":"Cancer"},{"key":"10.1038\/mt.2008.32_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0007-1226(03)00028-6","article-title":"British Association of Dermatologists; British Association of Plastic Surgeons, Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma","volume":"56","author":"Motley","year":"2003","journal-title":"Br J Plast Surg"},{"key":"10.1038\/mt.2008.32_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11864-002-0009-0","article-title":"Nonmelanoma skin cancer","volume":"3","author":"Nguyen","year":"2002","journal-title":"Curr Treat Options Oncol"},{"key":"10.1038\/mt.2008.32_bib16","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1200\/JCO.1999.17.10.3313","article-title":"Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA\/DMRIE\/DOPE lipid complex: phase I\/II experience","volume":"17","author":"Galanis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2008.32_bib17","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br J Cancer"},{"issue":"7 Pt 2","key":"10.1038\/mt.2008.32_bib18","doi-asserted-by":"crossref","first-page":"2353s","DOI":"10.1158\/1078-0432.CCR-05-2503","article-title":"Cytokine-based therapy and biochemotherapy for advanced melanoma","volume":"12","author":"Atkins","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2008.32_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/CCO.0b013e32801497d7","article-title":"Melanoma immunology: past, present and future","volume":"19","author":"Parmiani","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1038\/mt.2008.32_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.cco.0000142070.45097.68","article-title":"A review of recent findings involving interleukin-2-based cancer therapy","volume":"16","author":"Eklund","year":"2004","journal-title":"Curr Opin Oncol"},{"issue":"suppl. 1","key":"10.1038\/mt.2008.32_bib21","first-page":"S79","article-title":"An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer","volume":"3","author":"Yang","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"10.1038\/mt.2008.32_bib22","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-05-4128","article-title":"Tumor-driven evolution of immunosuppressive networks during malignant progression","volume":"66","author":"Kim","year":"2006","journal-title":"Cancer Res"},{"issue":"7 Pt 2","key":"10.1038\/mt.2008.32_bib23","doi-asserted-by":"crossref","first-page":"2346s","DOI":"10.1158\/1078-0432.CCR-05-2540","article-title":"Immune monitoring of T-cell responses in cancer vaccine development","volume":"12","author":"Keilholz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2008.32_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.immunol.24.021605.090733","article-title":"Human T cell responses against melanoma","volume":"24","author":"Boon","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1038\/mt.2008.32_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semradonc.2005.12.008","article-title":"Treatment of oligometastases after successful immunotherapy","volume":"16","author":"Yang","year":"2006","journal-title":"Semin Radiat Oncol"},{"key":"10.1038\/mt.2008.32_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.cad.0000182748.47353.51","article-title":"Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma","volume":"17","author":"Grande","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1038\/mt.2008.32_bib27","first-page":"1006","article-title":"Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2","volume":"50","author":"Krastev","year":"2003","journal-title":"Hepatogastroenterology"},{"issue":"suppl. 1","key":"10.1038\/mt.2008.32_bib28","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","article-title":"Immune responses to gene therapy vectors: influence on vector function and effector mechanisms","volume":"11","author":"Bessis","year":"2004","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2008.32_bib29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/hum.2004.15.1157","article-title":"The innate immune response to adenovirus vectors","volume":"15","author":"Muruve","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2008.32_bib30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.1999.17.2.529","article-title":"Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer","volume":"17","author":"Franzke","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2008.32_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.cgt.7700309","article-title":"Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8+ T-cell immunity and NK activity","volume":"8","author":"Slos","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2008.32_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1084\/jem.190.5.705","article-title":"High frequencies of naive Melan-A\/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals","volume":"190","author":"Pittet","year":"1999","journal-title":"J Exp Med"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616317154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616317154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T20:10:46Z","timestamp":1588536646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616317154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S1525001616317154"],"URL":"https:\/\/doi.org\/10.1038\/mt.2008.32","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}